Cybin has partnered with Clinilabs to carry out its Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analogue.
Delic Holdings Corp subsidiary, Delic Labs, has received a Health Canada 56 Research Exemption that will allow scientists to conduct research and perform tests on psychedelic and...
Numinus’ acquisition of Novamind will see the complementary businesses create a North American platform for psychedelic therapy and research.
The first healthy, psychedelic-naïve volunteers have been dosed in Beckley Psytech’s Phase I clinical trial assessing safety and pharmacokinetics of its second innovative formulation of 5-MeO-DMT...
A new study has shown that higher ratings of mystical-type experiences induced by psychedelics were associated with greater increases in the attribution of consciousness.
Cybin Inc.
Psyched Wellness and the National Research Council of Canada (NRC) have announced preliminary data from studies of the neuroprotective and anti-inflammatory properties of AME-1.
Leading UK psychedelics company Compass Pathways is entering into a pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate...
A systemic review of evidence has shown a lack of scientific research describing the interactions between widely used psychiatric medications and psychedelics like psilocybin and MDMA.
A new study has shown how changes in subjective awareness induced by psychedelics are anatomically rooted in specific neurotransmitter receptor systems.